Filter
Reset all

Subjects

Content Types

Countries

API

Data access

Data access restrictions

Database access

Database access restrictions

Data licenses

Data upload

Data upload restrictions

Enhanced publication

Institution responsibility type

Institution type

Keywords

Metadata standards

Provider types

Quality management

Repository languages

Software

Repository types

  • * at the end of a keyword allows wildcard searches
  • " quotes can be used for searching phrases
  • + represents an AND search (default)
  • | represents an OR search
  • - represents a NOT operation
  • ( and ) implies priority
  • ~N after a word specifies the desired edit distance (fuzziness)
  • ~N after a phrase specifies the desired slop amount
  • 1 (current)
Found 2 result(s)

Central Neuroimaging Data Archive

CNDA

Subject(s)
Content type(s)
Country
The Central Neuroimaging Data Archive (CNDA) allows for sharing of complex imaging data to investigators around the world, through a simple web portal. The CNDA is an imaging informatics platform that provides secure data management services for Washington University investigators, including source DICOM imaging data sharing to external investigators through a web portal, cnda.wustl.edu. The CNDA’s services include automated archiving of imaging studies from all of the University’s research scanners, automated quality control and image processing routines, and secure web-based access to acquired and post-processed data for data sharing, in compliance with NIH data sharing guidelines. The CNDA is currently accepting datasets only from Washington University affiliated investigators. Through this platform, the data is available for broad sharing with researchers both internal and external to Washington University.. The CNDA overlaps with data in oasis-brains.org https://www.re3data.org/repository/r3d100012182, but CNDA is a larger data set.

Coronavirus Antiviral Research Database

COVDB

Subject(s)
Content type(s)
Country
The Coronavirus Antiviral Research Database is designed to expedite the development of SARS-CoV-2 antiviral therapy. It will benefit global coronavirus drug development efforts by (1) promoting uniform reporting of experimental results to facilitate comparisons between different candidate antiviral compounds; (2) identifying gaps in coronavirus antiviral drug development research; (3) helping scientists, clinical investigators, public health officials, and funding agencies prioritize the most promising compounds and repurposed drugs for further development; (4) providing an objective, evidenced-based, source of information for the public; and (5) creating a hub for the exchange of ideas among coronavirus researchers whose feedback is sought and welcomed. By comprehensively reviewing all published laboratory, animal model, and clinical data on potential coronavirus therapies, the Database makes it unlikely that promising treatment approaches will be overlooked. In addition, by making it possible to compare the underlying data associated with competing treatment strategies, stakeholders will be better positioned to prioritize the most promising anti-coronavirus compounds for further development.